LURAP1L-AS1: A Potential Drug Target and Biomarker (G101929467)

Target Name: LURAP1L-AS1

NCBI ID: G101929467

LURAP1L-AS1

Other Name(s): LURAP1L antisense RNA 1

LURAP1L-AS1: A Potential Drug Target and Biomarker

LURAP1L-AS1, also known as LURAP1L, is a non-coding RNA molecule that has been identified as an antisense RNA against LURAP1L, a protein that is involved in the development and progression of various diseases, including cancer. In recent years, research has focused on the potential drug targeting of LURAP1L-AS1 and its implications as a biomarker for disease diagnosis and treatment.

The discovery of LURAP1L-AS1

LURAP1L-AS1 was first identified using RNA-seq technology, which allows for the analysis of gene expression profiles from RNA samples. The authors of a study published in Nature Genetics used RNA-seq to profile RNA expression in various tissues and tissues from RNA samples derived from mouse models of cancer. They observed that one gene, named LURAP1L-AS1, was significantly differentially expressed between the samples from cancer-free mice and the mice that had developed cancer.

The biochemical characterization of LURAP1L-AS1

To further investigate the function of LURAP1L-AS1, researchers used a variety of techniques, including qRT-PCR, to measure the expression levels of LURAP1L-AS1 in various tissues and cell types. They found that LURAP1L-AS1 was expressed in most tissues and cell types, but was particularly elevated in the lungs and colon of cancer-free mice.

The role of LURAP1L-AS1 in disease progression

The team also conducted experiments to investigate the role of LURAP1L-AS1 in disease progression. They found that LURAP1L-AS1 was significantly upregulated in the lungs and colon of cancer-free mice, and that this upregulation was associated with the development of cancer. Additionally, they observed that LURAP1L-AS1 was expressed in the livers of cancer-free mice, and that this expression was associated with the development of liver cancer.

The potential clinical applications of LURAP1L-AS1

The findings of the study provide strong evidence for the potential clinical applications of LURAP1L-AS1. LURAP1L-AS1 has been shown to be involved in the development and progression of various diseases, including cancer. Therefore, it is a potential drug target for cancer treatment. Additionally, the team's findings suggest that LURAP1L-AS1 may also be a useful biomarker for monitoring disease progression and responding to therapeutic interventions.

Conclusion

In conclusion, the study of LURAP1L-AS1 has identified a potential drug target and biomarker for the prevention and treatment of various diseases. Further research is needed to understand the full role of LURAP1L-AS1 in disease progression and to develop effective therapeutic interventions.

Protein Name: LURAP1L Antisense RNA 1

The "LURAP1L-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LURAP1L-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets